These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 33523913)

  • 21. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
    Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
    Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
    Duraiswamy J; Freeman GJ; Coukos G
    Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition.
    Gu CL; Zhu HX; Deng L; Meng XQ; Li K; Xu W; Zhao L; Liu YQ; Zhu ZP; Huang HM
    Acta Pharmacol Sin; 2022 Mar; 43(3):672-680. PubMed ID: 33990766
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma.
    Wang Y; Zhang X; Xu C; Nan Y; Fan J; Zeng X; Kwon BS; Ju D
    Front Immunol; 2022; 13():1004475. PubMed ID: 36544785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody.
    Park JA; Espinosa-Cotton M; Guo HF; Monette S; Cheung NV
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36990507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
    Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
    Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
    Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
    Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
    Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
    J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Striking the Balance with a PD-L1×4-1BB Bispecific Antibody.
    Ha J; Grippin AJ; Kim BYS; Jiang W
    Cancer Res; 2024 May; 84(10):1546-1547. PubMed ID: 38745496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy.
    Shi N; Zhou Y; Liu Y; Zhang R; Jiang X; Ren C; Gao X; Luo L
    Front Immunol; 2022; 13():1047610. PubMed ID: 36518768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
    Rubio-Pérez L; Lázaro-Gorines R; Harwood SL; Compte M; Navarro R; Tapia-Galisteo A; Bonet J; Blanco B; Lykkemark S; Ramírez-Fernández Á; Ferreras-Gutiérrez M; Domínguez-Alonso C; Díez-Alonso L; Segura-Tudela A; Hangiu O; Erce-Llamazares A; Blanco FJ; Santos C; Rodríguez-Peralto JL; Sanz L; Álvarez-Vallina L
    Oncoimmunology; 2023; 12(1):2205336. PubMed ID: 37114242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.
    Warmuth S; Gunde T; Snell D; Brock M; Weinert C; Simonin A; Hess C; Tietz J; Johansson M; Spiga FM; Heiz R; Flückiger N; Wagen S; Zeberer J; Diem D; Mahler D; Wickihalder B; Muntwiler S; Chatterjee B; Küttner B; Bommer B; Yaman Y; Lichtlen P; Urech D
    Oncoimmunology; 2021; 10(1):2004661. PubMed ID: 35844969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.
    Vezys V; Penaloza-MacMaster P; Barber DL; Ha SJ; Konieczny B; Freeman GJ; Mittler RS; Ahmed R
    J Immunol; 2011 Aug; 187(4):1634-42. PubMed ID: 21742975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
    Nelson MH; Fritzell S; Miller R; Werchau D; Van Citters D; Nilsson A; Misher L; Ljung L; Bader R; Deronic A; Chunyk AG; Schultz L; Varas LA; Rose N; Håkansson M; Gross J; Furebring C; Pavlik P; Sundstedt A; Veitonmäki N; Ramos HJ; Säll A; Dahlman A; Bienvenue D; von Schantz L; McMahan CJ; Askmyr M; Hernandez-Hoyos G; Ellmark P
    Mol Cancer Ther; 2023 Jan; 22(1):89-101. PubMed ID: 36343381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 blockade-unresponsive human tumor-infiltrating CD8
    Kim KH; Kim HK; Kim HD; Kim CG; Lee H; Han JW; Choi SJ; Jeong S; Jeon M; Kim H; Koh J; Ku BM; Park SH; Ahn MJ; Shin EC
    Cell Mol Immunol; 2021 Feb; 18(2):385-397. PubMed ID: 32332901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.
    Hinner MJ; Aiba RSB; Jaquin TJ; Berger S; Dürr MC; Schlosser C; Allersdorfer A; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Matis L; Olwill SA
    Clin Cancer Res; 2019 Oct; 25(19):5878-5889. PubMed ID: 31138587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target.
    Freeman ZT; Nirschl TR; Hovelson DH; Johnston RJ; Engelhardt JJ; Selby MJ; Kochel CM; Lan RY; Zhai J; Ghasemzadeh A; Gupta A; Skaist AM; Wheelan SJ; Jiang H; Pearson AT; Snyder LA; Korman AJ; Tomlins SA; Yegnasubramanian S; Drake CG
    J Clin Invest; 2020 Mar; 130(3):1405-1416. PubMed ID: 32015231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
    Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
    Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.